SILO PHARMA INC
SILONASDAQTrading Snapshot
- Day Range
- $1.67 β $1.82
- 52-Week Range
- $1.10 β $10.42
- Volume (shares)
- 41,652
- Avg Volume (shares)
- β
- Shares Outstanding
- 1.9M
- Next Earnings
- 2027-03-26
Fundamentals Snapshot
- Annual Revenue
- $72,102
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- 50.2x
- EPS (TTM)
- $-5.33
- Dividend Yield
- β
- Dilution (1yr)
- +197.0%
SILO PHARMA INC
SILOAbout SILO PHARMA INC
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Silo Pharma's QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software SARASOTA, FLA., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (βSiloβ or βthe Company

Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
Allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses SARASOTA, FLA., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (βSiloβ or βthe Companyβ), a de

Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
SARASOTA, FLA., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (βSiloβ or βthe Companyβ), β), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a

InterCure (NASDAQ:INCR) & Silo Pharma (NASDAQ:SILO) Financial Review
InterCure (NASDAQ: INCR - Get Free Report) and Silo Pharma (NASDAQ: SILO - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the streng